Cardinal Health, a global leader in healthcare services and products, has officially announced the appointment of Anita Zielinski as its new Chief Accounting Officer, a move that signals a strategic shift in its executive financial leadership. Zielinski, who most recently served as the interim Chief Financial Officer and Chief Accounting Officer at Baxter International, is scheduled to transition into her new role on November 5, 2025. This transition follows her departure from Baxter, which is slated for September 15, 2025. The dual announcements from both Baxter and Cardinal Health, released during the first week of August, underscore a period of significant executive movement within the medical technology and healthcare distribution sectors.
The recruitment of Zielinski is seen as a major acquisition for Cardinal Health, which is currently navigating a complex period of market expansion and operational streamlining. According to official securities filings, Zielinski will succeed Mary Scherer, the outgoing Chief Accounting Officer at Cardinal Health. To secure Zielinski’s expertise, Cardinal Health has structured a highly competitive compensation package. This includes a one-time cash sign-on bonus of $750,000 and $1 million in restricted share units (RSUs). The RSUs are designed as a long-term incentive, with a vesting schedule spanning three years, contingent upon her continued service and the company’s performance metrics.
Professional Trajectory and Experience
Anita Zielinski brings a wealth of experience to Cardinal Health, characterized by deep expertise in corporate governance, financial reporting, and large-scale organizational management. Her tenure at Baxter International, while relatively brief, was marked by intense responsibility. She joined Baxter in February 2025 as the Chief Accounting Officer and Controller. However, her role expanded significantly in March 2025 when she was tapped to serve as the interim Chief Financial Officer following the departure of Joel Grade.
During her months as interim CFO, Zielinski was tasked with maintaining financial stability for a company undergoing a massive structural overhaul. Her ability to manage the dual responsibilities of CAO and interim CFO during a period of corporate divestiture and disaster recovery was noted by industry analysts as a testament to her operational resilience.
Prior to her time at Baxter, Zielinski spent seven years at Sysco, the global leader in food service distribution, where she honed her skills in managing complex supply chain finances. Perhaps most foundational to her career was her twenty-year tenure at Ernst & Young (EY). At EY, one of the "Big Four" accounting firms, she served as a partner, providing audit and advisory services to high-cap public companies. This extensive background in public accounting is particularly relevant for Cardinal Health, a Fortune 500 entity that requires rigorous adherence to Securities and Exchange Commission (SEC) regulations and Transparent financial disclosures.
The Context of Baxter International’s Leadership Transition
Zielinski’s departure leaves a temporary void in Baxter International’s executive suite at a time when the company is searching for a permanent Chief Financial Officer. Baxter has seen a flurry of leadership changes over the past year, reflecting a broader effort to revitalize the company’s market position. In July 2025, Baxter named Andrew Hider as its new Chief Executive Officer, a move intended to steer the company through its post-divestiture phase.
The leadership churn at Baxter is occurring against a backdrop of significant operational challenges. The company has spent much of 2024 and 2025 recovering from catastrophic hurricane damage that impacted its primary manufacturing facilities. This disruption necessitated a massive logistical effort to ensure the continued supply of life-saving medical products, particularly intravenous (IV) solutions, for which Baxter holds a significant market share.
Simultaneously, Baxter has been executing a strategic "simplification" plan. This included the divestiture of its Kidney Care unit—now operating as a standalone entity named Vantive—and the sale of its BioPharma Solutions business. These moves were designed to sharpen Baxter’s focus on its core medical technology and hospital solutions portfolios. Zielinski’s role in overseeing the financial reporting for these complex carve-outs was critical to the company’s ability to maintain investor confidence during the transition.
Strategic Implications for Cardinal Health
For Cardinal Health, appointing a CAO with Zielinski’s pedigree is a calculated move to strengthen its financial infrastructure. As a major distributor of pharmaceuticals and a manufacturer of medical and surgical products, Cardinal Health operates on thin margins where financial precision is paramount. The role of the Chief Accounting Officer is vital in ensuring that the company’s multi-billion dollar revenue streams are accurately tracked and reported across its diverse global segments.
The transition from Mary Scherer to Anita Zielinski comes at a time when Cardinal Health is focusing on "long-term sustainable growth." The company has been active in capital redeployment, focusing on share buybacks and dividend increases, while also investing in its "at-home" healthcare solutions and specialty pharmacy services. Zielinski’s experience at Sysco—another distribution giant—provides her with a unique perspective on the logistical and inflationary pressures that affect large-scale distribution networks.
Industry analysts suggest that the $1.75 million initial compensation package offered to Zielinski reflects the high demand for "battle-tested" finance executives who can navigate the complexities of the current MedTech environment. The three-year vesting period of her RSUs further aligns her personal financial interests with the long-term stock performance of Cardinal Health, a standard practice for top-tier executive retentions.
Chronology of Executive and Corporate Events
To understand the impact of this move, it is necessary to look at the timeline of events leading up to the November 5 start date:
- February 2025: Anita Zielinski joins Baxter International as Chief Accounting Officer and Controller.
- March 2025: Joel Grade steps down as Baxter’s CFO; Zielinski is appointed interim CFO while retaining her CAO and Controller duties.
- July 2025: Andrew Hider is appointed CEO of Baxter International, succeeding the previous leadership as the company stabilizes after hurricane-related manufacturing disruptions.
- August 2025 (First Week): Cardinal Health and Baxter International concurrently announce Zielinski’s upcoming move.
- September 15, 2025: Zielinski’s final day at Baxter International.
- September 16 – November 4, 2025: An expected transition period during which Baxter will likely rely on internal financial leadership or name a permanent CFO successor.
- November 5, 2025: Zielinski officially assumes the role of Chief Accounting Officer at Cardinal Health.
Broader Industry Impact and Financial Analysis
The movement of high-level executives between major healthcare players like Baxter and Cardinal Health highlights the competitive nature of the MedTech talent pool. As companies face increasing pressure from activist investors and fluctuating global demand, the "C-suite" has become more dynamic.
The role of the Chief Accounting Officer has evolved beyond mere bookkeeping. In the modern corporate landscape, the CAO is a strategic partner to the CEO and CFO, responsible for implementing digital transformation in financial systems, managing global tax implications, and overseeing Environmental, Social, and Governance (ESG) reporting. Zielinski’s extensive history with EY suggests she is well-equipped to handle the increasing regulatory scrutiny surrounding corporate sustainability and supply chain transparency.
Furthermore, Baxter’s ongoing search for a permanent CFO will be a key story to watch in the coming months. The company’s ability to attract a top-tier candidate will depend largely on how the market perceives its post-divestiture growth potential. With the Kidney Care and BioPharma units gone, Baxter is a leaner, more focused organization, but it remains under pressure to deliver consistent quarterly earnings growth following the disruptions of the previous year.
Cardinal Health, conversely, appears to be in a "consolidation and optimization" phase. By bringing in Zielinski, they are ensuring that their back-office financial operations are led by an individual who has successfully navigated one of the most turbulent periods in Baxter’s recent history.
Conclusion
The appointment of Anita Zielinski as Chief Accounting Officer of Cardinal Health represents a significant milestone for both the executive and the companies involved. For Zielinski, it is a return to a specialized focus on accounting leadership at a massive scale, supported by a lucrative incentive package. For Cardinal Health, it is an infusion of veteran leadership during a period of strategic growth. For Baxter International, it marks the end of a critical interim period and the beginning of a new chapter in its ongoing search for a permanent financial leadership team. As the healthcare industry continues to grapple with macroeconomic shifts and internal restructuring, the movement of leaders like Zielinski remains a primary indicator of corporate health and strategic intent.
